News

New listing of BIOMAXIMA

2022-01-31 16:47:22

The company BIOMAXIMA S.A. was newly listed on the GPW Main Market on 31 January 2022.
BIOMAXIMA S.A. is the 429th company listed on the Main Market and the first new listing on the Main Market in 2022.

Key information

company name	BIOMAXIMA S.A.
ticker/abbreviated name	BIOMAXIMA/BMX
market (main/parallel)	Main Market
seat	Lublin
Polish/foreign (other listing markets)	Polish
companies listed on the regulated market	429
new listings in 2022	1
transfers from NC in 2022	1
core business	production and distribution of medical reagents and tests, in vitro diagnostic equipment, research and development
business sector	Biotechnology
companies in the sector	11
IPO/public sale	Not applicable
issue/selling price	Not applicable
public offering value:	Not applicable
company capitalisation*	PLN 160,444,800
% free float in shares subject to the application	73.6 %
free float value*	PLN 118,084,922
% free float in all shares	73.6 %
free float value* (in all shares)	PLN 118,084,922
number of shareholders (shares subject to the application)	as series A, B, C, D shares are traded in the NewConnect ATS, the total number of the Company’s shareholders cannot be determined
Investment Firm	Dom Maklerski Banku Ochrony Środowiska S.A.
Financial Advisor	none
Legal Advisor	TaylorWessing E. Stobiecka Kancelaria Prawna sp. k.
Audit Firm	Grant Thornton Polska Sp. z o.o. sp. k.

*as at the closing price of the shares at 27 January 2022 (PLN 37.14)

Issuer’s history and business

The Company’s shares were listed in the NewConnect Alternative Trading System since 8 June 2010.

The history of the Issuer dates back to 2002, when Biomaxima Sp. z o.o. was established. Since 2008, the Issuer has operated as a joint stock company.

The Issuer is a manufacturer of solutions for in vitro diagnostics of infectious diseases and product safety testing in industry. The Issuer is also a distributor in Poland of products of global diagnostic companies.

The Issuer’s core business includes the production and sale of proprietary products including the following technologies (technology platforms):

- production of microbiological media, as well as supplements, additives and other components of microbiological media, intended for the industrial laboratory market;

- production of diffusion systems for determining drug susceptibility and resistance mechanisms of bacteria and fungi;

- manufacture of rapid diagnostic tests for detection of infectious diseases, tumour markers, markers of myocardial infarction, addictive drugs along with readers

- production of proprietary diagnostic reagents for testing biochemical parameters of blood and other body fluids along with analysers;

As of 2019, the Issuer is also building up its competences in the fifth technology platform: molecular diagnostics. Initially, the Issuer introduced rt-PCR tests for industrial laboratories in cooperation with a German partner. In 2020, in connection with the COVID-19 pandemic, the Issuer launched rt-PCR tests for SARS-CoV-2 virus in cooperation with a Spanish partner. It now offers a family of assays for the determination and differentiation of upper respiratory tract pathogens, including SARS-CoV-2.

The Issuer has a plant in Lublin, which was expanded in 2017 – 2018, providing production infrastructure for the technologies described above in the form of automated production lines (depending on the technology) which were individually designed and implemented with the participation of the Issuer’s engineers.

In addition, the Group’s activities include the distribution (trade) of products complementary to the Issuer’s own product range as well as training activities. As at 30 September 2021, the Company had 101 employees under employment contracts. The Company also commissions some work under civil law contracts.

Issuer’s share capital

The Issuer’s share capital entered in the Business Register amounts to PLN 4,320,000 and is divided into 4,320,000 ordinary bearer shares with a nominal value of PLN 1 per share, including:

1,440,000 series A ordinary bearer shares;
600,000 series B ordinary bearer shares;
1,000,000 series C ordinary bearer shares;
690,000 series D ordinary bearer shares;
190,000 series E ordinary bearer shares;
400,000 series F ordinary bearer shares.

The Issuer did not conduct a public offering in connection with the new listing on the GPW Main Market.

Issuer’s selected financials:

[PLN’000]	Q1-3 2021	2020	2019
Sales revenue	56,033	61,281	29,761
Net profit	8,248	7,949	-901
Total assets	50,895	47,701	36,059
Equity	27,160	19,885	9,321
Liabilities and provisions	23,735	27,815	26,738
Net cash flows (net change)	-1,938	3,880	-518
Cash	2,448	4,386	506